Positron emission tomography measures of benzodiazepine receptors in Huntington's disease

We performed positron emission tomographic (PET) measurements of the regional distribution volume of benzodiazepine receptors and regional glucose metabolism in 6 drug‐free patients with early Huntington's disease following injection of [11C] flumazenil, a nonsubtype selective central benzodiazepine receptor antagonist, and 18F‐2‐fluoro‐2‐deoxy‐D‐glucose, respectively. Flumazenil data were analyzed with a recently developed two‐compartment, two‐parameter tracer kinetic model. Benzodiazepine receptor density is related to distribution volume for flumazenil. In comparison with a group of healthy volunteers, benzodiazepine receptor density was significantly decreased in the caudate nucleus. Glucose metabolism was significantly reduced not only in the caudate nucleus but also in the putamen and thalamus. The changes in benzodiazepine receptor density observed in the caudate nucleus are commensurate with data obtained in postmortem autoradiographic studies of receptor density. Based on such postmortem studies we also anticipated changes in putamen and thalamic benzodiazepine receptor density. However, relatively little is known on receptor changes in early Huntington's disease, because the autoradiographic data available were obtained mostly in patients with advanced disease. The decreased glucose metabolism in the caudate and putamen agrees well with previously published results of PET studies, whereas metabolic impairment of the thalamus has not yet been described in Huntington's disease. The present study suggests that regional metabolism and γ‐aminobutyric acid (GABA)‐benzodiazepine receptor changes in subcortical structures of patients with early Huntington's disease do not occur with the same time course: Caudate benzodiazepine receptor density is already severely impaired when other subcortical structures reveal only minor abnormalities. Impairment of neuronal metabolism seems to predate GABA/benzodiazepine receptor changes since the putamen and thalamus demonstrate metabolic impairment without detectable loss of benzodiazepine receptor density.

[1]  J. Mazziotta,et al.  Local cerebral glucose utilization in symptomatic and presymptomatic Huntington's disease. , 1985, Research publications - Association for Research in Nervous and Mental Disease.

[2]  H. Herzog,et al.  Cortical and subcortical glucose consumption measured by PET in patients with Huntington's disease. , 1990, Brain : a journal of neurology.

[3]  J. E. Vaughn,et al.  The GABA Neurons and their axon terminals in rat corpus striatum as demonstrated by GAD immunocytochemistry , 1979, The Journal of comparative neurology.

[4]  J. Mazziotta,et al.  Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease. , 1987, The New England journal of medicine.

[5]  L. Eriksson,et al.  Imaging of [11C]-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. , 1985, Journal of psychiatric research.

[6]  C. Y. Chan,et al.  Modulation of Neuronal Function through Benzodiazepine Receptors: Biochemical and Electrophysiological Studies of Neurons in Primary Monolayer Cell Culture , 1984, Annals of the New York Academy of Sciences.

[7]  C. Markham,et al.  Cerebral metabolism and atrophy in huntington's disease determined by 18FDG and computed tomographic scan , 1982, Annals of neurology.

[8]  J C Mazziotta,et al.  Quantitation in Positron Emission Computed Tomography: 5. Physical–Anatomical Effects , 1981, Journal of computer assisted tomography.

[9]  Scott T. Grafton,et al.  A comparison of neurological, metabolic, structural, and genetic evaluations in persons at risk for Huntington's disease , 1990, Annals of neurology.

[10]  Shirley Hansen,et al.  Huntington's Chorea , 1973 .

[11]  R. Hichwa,et al.  PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline , 1986, Annals of neurology.

[12]  J. Penney,et al.  Quantitative autoradiography of GABA and benzodiazepine binding in studies of mammalian and human basal ganglia function , 1986 .

[13]  J. Waddington,et al.  Denervation supersensitivity in the striatonigral GABA pathway , 1978, Nature.

[14]  L. Iversen,et al.  Alterations of brain neurotransmitter receptor binding in Huntington's chorea , 1976, Brain Research.

[15]  J. Richards,et al.  Agonist and antagonist benzodiazepine receptor interaction in vitro , 1981, Nature.

[16]  D E Kuhl,et al.  Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  A. Davenport,et al.  Quantitative receptor autoradiography , 1986, Nature.

[18]  J. Penney,et al.  Quantitative autoradiography of neurotransmitter receptors in Huntington disease , 1982, Neurology.

[19]  E. Bird,et al.  Alterations in the benzodiazepine receptor of Huntington's diseased human brain , 1979, Brain Research.

[20]  J. Mazziotta,et al.  TOMOGRAPHIC MAPPING OF HUMAN CEREBRAL METABOLISM: NORMAL UNSTIMULATED STATE , 1981 .

[21]  S. Fahn,et al.  Huntington disease , 1979, Neurology.

[22]  J. Penney,et al.  The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.

[23]  R. Macdonald,et al.  Differential regulation of γ‐aminobutyric acid receptor channels by diazepam and phenobarbital , 1989 .

[24]  Mental Disease,et al.  Brain imaging and brain function , 1985 .

[25]  J. Penney,et al.  Benzodiazepine and GABA receptors in early Huntington's disease , 1984, Neurology.

[26]  E. Bird,et al.  Alterations in 3H-GABA binding in Huntington's chorea. , 1977, Life sciences.

[27]  Michael E. Phelps,et al.  Quantitation in Positron Emission Computed Tomography , 1980 .

[28]  S. Folstein,et al.  Neurotransmitter receptor alterations in Huntington's disease: Autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes , 1985, Annals of neurology.

[29]  J. Baron,et al.  Regional Specific Binding of [11C]RO 15 1788 to Central Type Benzodiazepine Receptors in Human Brain: Quantitative Evaluation by PET , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[30]  R. Dom,et al.  Neuropathology of Huntington's chorea , 1976, Neurology.

[31]  D E Kuhl,et al.  Differentiation of Radioligand Delivery and Binding in the Brain: Validation of a Two-Compartment Model for [11C]Flumazenil , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[32]  R. Koeppe,et al.  Parametric in vivo imaging of benzodiazepine receptor distribution in human brain , 1991, Annals of neurology.

[33]  J. Waddington,et al.  Characterisation of denervation supersensitivity in the striatonigral GABA pathway of the kainic acid-lesioned rat and in Huntington's disease , 1979, Brain Research Bulletin.

[34]  K A Frey,et al.  Changes in [3H]muscimol binding in substantia nigra, entopeduncular nucleus, globus pallidus, and thalamus after striatal lesions as demonstrated by quantitative receptor autoradiography , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  T. Perry,et al.  Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain. , 1973, The New England journal of medicine.

[36]  O. Inoue,et al.  Visualization of specific binding sites of benzodiazepine in human brain. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.